Flyer: Cited Antibodies Q2 2024 from GeneTex

by | Apr 24, 2024 | Cancer, COVID-19, Immunology, Neurology, Stem Cell

FLYER FROM GENETEX

GENETEX: CITED ANTIBODIES Q2 2024

GeneTex released a flyer highlighting featured antibodies cited in various international publications of different research areas, including cancer research, cell biology research, neuroscience research and infectious disease research.

Download flyer now to explore more.

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

ABOUT GENETEX

With a 27-year production history, GeneTex continues to distinguish itself by emphasizing reagent validation.

Founded by scientists for scientists, GeneTex understands that researchers expect and demand product fidelity.

With a 27-year production history, GeneTex distinguishes itself by emphasising reagent validation. Poorly characterized antibodies remain an industry-wide challenge that impacts progress in the life sciences and biomedicine.

At GeneTex, product reliability is their primary concern. Stringent protocols have been established to validate their antibodies for various applications, including WB, IP, IHC, ICC/IF, FACS, and ELISA, using cell lines with known target protein expression levels and a diverse array of tissue samples. Lot-to-lot antibody performance is maintained through a combination of fully characterized reference lots, clone verification, and thorough quality control.

GeneTex products are made to standards outlined in quality management systems ISO 9001:2015, ISO 13485:2016 and ISO 14001: 2015.

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

IF YOU NEED QUALITY RECOMBINANT ANTIBODIES, WE CAN HELP.

Contact us
Share This